Adage Capital Partners
SYRE icon

Adage Capital Partners’s Spyre Therapeutics SYRE Stock Holding History

Adage Capital Partners’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-610,200
Closed -$9.13M – 972
2025
Q2 		$9.13M Sell
610,200
-193,000
-24% -$2.86M 0.02% 632
2025
Q1 		$13M Sell
803,200
-226,800
-22% -$4.72M 0.02% 529
2024
Q4 		$24M Sell
1,030,000
-25,000
-2% -$733K 0.04% 396
2024
Q3 		$31M Sell
1,055,000
-97,411
-8% -$2.71M 0.05% 331
2024
Q2 		$27.1M Buy
1,152,411
+47,211
+4% +$1.59M 0.05% 361
2024
Q1 		$41.9M Buy
1,105,200
+105,200
+11% +$3.05M 0.08% 267
2023
Q4 		$21.5M Buy
+1,000,000
New +$13.8M 0.04% 408
2023
Q2 		– Sell
-60,000
Closed -$435K – 926
2023
Q1 		$435K Hold
60,000
– – ﹤0.01% 820
2022
Q4 		$675K Hold
60,000
– – ﹤0.01% 855
2022
Q3 		$789K Hold
60,000
– – ﹤0.01% 898
2022
Q2 		$758K Buy
+60,000
New +$2.1M ﹤0.01% 933
2022
Q1 		– Sell
-40,000
Closed -$4.75M – 1132
2021
Q4 		$4.75M Sell
40,000
-100,000
-71% -$15.8M 0.01% 821
2021
Q3 		$27.8M Buy
140,000
+18,017
+15% +$3.15M 0.05% 352
2021
Q2 		$21.2M Buy
121,983
+4,057
+3% +$737K 0.04% 446
2021
Q1 		$23.3M Sell
117,926
-1,754
-1% -$337K 0.05% 393
2020
Q4 		$23.5M Hold
119,680
– – 0.05% 379
2020
Q3 		$21.2M Buy
119,680
+4,000
+3% +$740K 0.05% 358
2020
Q2 		$26.8M Buy
115,680
+56,936
+97% +$10.8M 0.07% 312
2020
Q1 		$6.84M Hold
58,744
– – 0.02% 532
2019
Q4 		$11.2M Hold
58,744
– – 0.03% 519
2019
Q3 		$11.3M Hold
58,744
– – 0.03% 500
2019
Q2 		$10.1M Hold
58,744
– – 0.03% 531
2019
Q1 		$11.8M Buy
58,744
+400
+0.7% +$83.4K 0.03% 496
2018
Q4 		$10.9M Buy
58,344
+21,716
+59% +$4.61M 0.03% 491
2018
Q3 		$8.76M Buy
36,628
+1,000
+3% +$234K 0.02% 564
2018
Q2 		$9.42M Buy
35,628
+25,628
+256% +$6.31M 0.02% 573
2018
Q1 		$2.48M Buy
+10,000
New +$1.81M 0.01% 669

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Adage Capital Partners's SYRE Position: Q3 2025 in Review

Adage Capital Partners sold out of Spyre Therapeutics (SYRE) in Q3 2025, closing a stake of 610,200 shares — an estimated $9.13M sold.

Adage Capital Partners first reported a position in SYRE in Q1 2018 and held it in 27 quarters. The position peaked at $41.9M in Q1 2024. 137 funds tracked by Wall St. Rank hold SYRE as of Q3 2025.

  • Adage Capital Partners reported no remaining Spyre Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Adage Capital Partners sold 610,200 Spyre Therapeutics shares in Q3 2025, an estimated $9.13M.
  • Adage Capital Partners first reported a position in Spyre Therapeutics in Q1 2018 and held it in 27 quarters.
  • Adage Capital Partners's Spyre Therapeutics position peaked at $41.9M in Q1 2024.
  • 137 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2025.

Based on Adage Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.